The enhancement of Nrf2 transcription with sulforaphane or melatonin could benefit patients with LONG COVID (Post-Acute Sequelae of SARS-CoV-2 or Post-COVID-Syndrome), a significant proportion (approximately 40%) of individuals with COVID-19 experiencing a variety of symptoms (loss of smell and/or taste, fatigue, cough, aching pain, brain fog, insomnia, shortness of breath, and tachycardia) after 12 weeks (Jarrott et al., 2022
V., Alenicheva, V., & Remcho, V
Nrf2 is inhibited by Kelch-like ECH-associated protein 1 (Keap1): specifically, it increases Nrf2 proteasome-mediated degradation [20,21]
Skjk-Brk, G., Zanetti, F
Effects of rs769217 and rs1001179 polymorphisms of catalase gene on blood catalase, carbohydrate and lipid biomarkers in diabetes mellitus